ncial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
HUMIRA(R) (adalimumab) is a registered trademark of Abbott Laboratories
REMICADE(R) (infliximab) is a registered trademark of Johnson & Johnson
Source: Cephalon, Inc.
Takeover Bid Conditions
Cephalon International Holdings, Inc.'s offer is proposed to be subject to the fulfillment of the following conditions. Capitalized terms have meanings set out in the glossary below.
(a) Minimum acceptance
Before and at the end of the Offer Period, Cephalon International has a relevant interest in at least 50.1% of Arana Shares.
(b) Adverse change conditions
(i) Material adverse change in respect of the Arana Group
During the Condition Period, no event, change or circumstance occurs, is announced or becomes known to Cephalon International (whether or not it becomes public) which has or could reasonably be expected to have a material adverse effect on the business, assets, liabilities, financial position, performance, profitability or prospects of the Arana Group taken as a whole.
(ii) IPage: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine news :1
. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs2
. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia3
. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer4
. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference5
. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.6
. Cephalon Appoints Gerald J. Pappert as General Counsel7
. Cephalon Reports Strong First Quarter Earnings8
. Cephalon Conference Call Invitation9
. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA10
. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing11
. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon